Evidence map›Paper›PMID 30157398›Full record

ArticleThe New England journal of medicine2018

Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.

Isobel M Blake, Margarita Pons-Salort, Natalie A Molodecky, Ousmane M Diop, Paul Chenoweth, Ananda S Bandyopadhyay, Michel Zaffran, Roland W Sutter, Nicholas C Grassly

Abstract read
In one paragraph

Article in The New England journal of medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Article
  2. Polio eradication: A perspective from the UK.New microbes and new infections · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Isobel M BlakeFrom the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).ORCID 0000-0002-3977-1318
Margarita Pons-SalortFrom the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).
Natalie A MolodeckyFrom the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).
Ousmane M DiopFrom the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).
Paul ChenowethFrom the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).
Ananda S BandyopadhyayFrom the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).
Michel ZaffranFrom the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).
Roland W SutterFrom the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).
Nicholas C GrasslyFrom the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).

Funding

Medical Research Council MR/R015600/1World Health Organization 001
6 · The paper itself

Abstract

backgroundMass campaigns with oral poliovirus vaccine (OPV) have brought the world close to the eradication of wild poliovirus. However, to complete eradication, OPV must itself be withdrawn to prevent outbreaks of vaccine-derived poliovirus (VDPV). Synchronized global withdrawal of OPV began with serotype 2 OPV (OPV2) in April 2016, which presented the first test of the feasibility of eradicating all polioviruses.

methodsWe analyzed global surveillance data on the detection of serotype 2 Sabin vaccine (Sabin-2) poliovirus and serotype 2 vaccine-derived poliovirus (VDPV2, defined as vaccine strains that are at least 0.6% divergent from Sabin-2 poliovirus in the viral protein 1 genomic region) in stool samples from 495,035 children with acute flaccid paralysis in 118 countries and in 8528 sewage samples from four countries at high risk for transmission; the samples were collected from January 1, 2013, through July 11, 2018. We used Bayesian spatiotemporal smoothing and logistic regression to identify and map risk factors for persistent detection of Sabin-2 poliovirus and VDPV2.

resultsThe prevalence of Sabin-2 poliovirus in stool samples declined from 3.9% (95% confidence interval [CI], 3.5 to 4.3) at the time of OPV2 withdrawal to 0.2% (95% CI, 0.1 to 2.7) at 2 months after withdrawal, and the detection rate in sewage samples declined from 71.0% (95% CI, 61.0 to 80.0) to 13.0% (95% CI, 8.0 to 20.0) during the same period. However, 12 months after OPV2 withdrawal, Sabin-2 poliovirus continued to be detected in stool samples (<0.1%; 95% CI, <0.1 to 0.1) and sewage samples (8.0%; 95% CI, 5.0 to 13.0) because of the use of OPV2 in response to VDPV2 outbreaks. Nine outbreaks were reported after OPV2 withdrawal and were associated with low coverage of routine immunization (odds ratio, 1.64 [95% CI, 1.14 to 2.54] per 10% absolute decrease) and low levels of population immunity (odds ratio, 2.60 [95% CI, 1.35 to 5.59] per 10% absolute decrease) within affected countries.

conclusionsHigh population immunity has facilitated the decline in the prevalence of Sabin-2 poliovirus after OPV2 withdrawal and restricted the circulation of VDPV2 to areas known to be at high risk for transmission. The prevention of VDPV2 outbreaks in these known areas before the accumulation of substantial cohorts of children susceptible to type 2 poliovirus remains a high priority. (Funded by the Bill and Melinda Gates Foundation and the World Health Organization.).

Indexed as

Poliovirus Vaccine, OralAdolescentAfricaAsiaChildChild, PreschoolDisease EradicationDisease OutbreaksFecesFemaleHumansInfantInfant, NewbornLogistic ModelsMalePoliomyelitisPoliovirus Vaccine, InactivatedPoliovirus Vaccine, OralSewage

Identifiers

PMID30157398
PMCPMC5985919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.